Feeds:
Posts
Comments

Archive for the ‘LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management’ Category

SOP for production of WordClouds for articles in the NEW GENRE Audio English-Spanish: BioMed e-Series – 18 Volumes in Medicine

Author: Aviva Lev-Ari, PhD, RN

LPBI Group’s SOP for production of WordClouds for articles in the NEW GENRE Audio English-Spanish: BioMed e-Series – 18 Volumes in Medicine https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/

include the following steps:

  1. To master WordItOut.com
  2. To apply it to all the articles in the following e-Series: Series A: 6 volumes, Series B: two volumes, Series C: two volumes, Series D: four volumes, Series E: four volumes

How to Start?

In PART B of every Volume you will find the electronic Table of Contents (eTOCs) of the e-Book

EXCEPTIONS:

In Series C: Cancer Volume One, eTOCs is in A.2

In Series B: Genomics Volume Two eTOCs is in A.2

STEPS in Production of WordClouds for each article in an e-Book

1.  You sign in to WordItOut.com

2.  You review all the steps to produce a WordCloud from an MS Word File

3.  You click on the URL of the 1st article in Volume 1

4.  You copy the article into an MS Word File

5.  You use this file on WordItOut.com website to produce a WordCloud for the 1st article

6.  You edit the output by removing meaning less words like connective term: the a, an, all, some, more

7.  You RUN again on a file that does not include the terms REMOVED

8.  You select a Scheme of colors for background and for fonts – optimize contrast for visibility and legibility

9.  YOU MAINTAIN 8, above for all the articles in ONE volume

10.              YOUR FINAL WordCloud for ONE article you upload to the Media Gallery on our Website. You write as Legend Based on Article Title: Quote here Title. Produced on date by your name

11.              You go to the 1st article you ADD Media, this WordCloud you had produced BELOW the NAME of the Author, Curator, Reporter. YOU UPDATE the article with your WordCloud. You View Page for QA

12.              You move to repeat all of the above for 2nd article in the same volume

13.              When you complete ONE volume you announce that Volume X has all the WordClouds in it

14.              You move to other Volumes in the series you are working on. If it is Series A, then you continue with Volumes Two, Three, Four, Five, Six

15.              YOU START WITH VOLUME ONE AND LET ME KNOW how many hours it took to create all the wordClouds, N=number of articles in Volume One

16.              We will decide regarding other Volumes in the same series

Read Full Post »

Relevance of Twitter.com forthcoming Payment System for Scientific Content Promotion and Monetization

Highlighted Text in BLUE, BLACK, GREEN, RED by Aviva Lev-Ari, PhD, RN

GIASOURCEN M. VOLPICELLI

Gian M. Volpicelli

SENIOR WRITER

Gian M. Volpicelli is a senior writer at WIRED, where he covers cryptocurrency, decentralization, politics, and technology regulation. He received a master’s degree in journalism from City University of London after studying politics and international relations in Rome. He lives in London.

SOURCE

https://www.wired.com/story/twitter-crypto-strategy/

 

BUSINESS

APR 5, 2022 7:00 AM

What Twitter Is Really Planning for Crypto

The duo behind Twitter Crypto say NFT profile pics and crypto tipping are just the beginning.

 

YOU MIGHT HAVE heard of crypto Twitter, the corner of the social network where accounts have Bored Apes as profile pictures, posts are rife with talk of tokens, blockchains, and buying the Bitcoin dip, and Elon Musk is venerated.

Then again, you might have heard of Twitter Crypto, the business unit devoted to developing the social network’s strategy for cryptocurrency, blockchains, and that grab-bag of decentralized technologies falling under the rubric of Web3. The team’s unveiling came in November 2021 via a tweet from the newly hired project lead, Tess Rinearson, a Berlin-based American computer scientist whose career includes stints at blockchain companies such as Tendermint and Interchain.

Rinearson joined Twitter at a crucial moment. Jack Dorsey, the vociferously pro-Bitcoin company CEO, would leave a few weeks later, to be replaced by CTO Parag Agrawal. Agrawal had played an instrumental role in Bluesky, a Twitter-backed project to create a protocol—possibly with blockchain components—to build decentralized social networks.

As crypto went mainstream globally and crypto Twitter burgeoned, the company tried to dominate the space. Under the stewardship of product manager Esther Crawford, in September 2021 Twitter introduced a “tipping” feature that helps creators on Twitter to receive Bitcoin contributions through Lightning—a network for fast Bitcoin payments. In January, Twitter allowed subscribers of Twitter’s premium service, Twitter Blue, to flaunt their NFTs as hexagonal profile pictures, through a partnership with NFT marketplace OpenSea.

Twitter Crypto is just getting started. While Rinearson works with people all across the company, her team is still under 10 people, although more hires are in the pipeline, judging from recent job postings. So it’s worth asking what is next. I caught up over a video call with Rinearson and Crawford to talk about where Twitter Crypto is headed. 

The conversation has been edited for clarity and brevity.

WIRED: Let’s start with the basics. Why does Twitter have a crypto unit?

Tess Rinearson: We really see crypto—and what we’re now calling Web3— as something that could be this incredibly powerful tool that would unlock a lot for our users. The whole crypto world is like an internet of money, an internet of value that our users can potentially tap into to create new ways of owning their content, monetizing their content, owning their own identity, and even relating to each other.

One of my goals is to build Twitter’s crypto unit in such a way that it caters to communities that go beyond just that core crypto community. I love the crypto Twitter space, obviously—I’m a very proud member of the crypto community. And at the same time, I recognize that people who are really deep in the crypto space may not relate to concepts, like for instance blockchain’s immutability, in the same way that someone who’s less intensely involved might feel about those things.

So a lot of what we try to think about is, what can we learn from this group of people who are super engaged and really, really, creative? And then, how can we translate some of that stuff into a format or a mechanism or a product that’s a little bit more accessible to people who don’t have that background?

How are you learning from crypto Twitter? Do you just follow a lot of accounts, do you actually talk to them? How does that learning experience play out?

Esther Crawford: It’s a combination. We have an amazing research team that sets up panel interviews and surveys. But we’re also embedded in the community itself and follow a bunch of accounts, sit on Twitter spaces, go to conferences and events, engage with customers in that way. That’s the way the research piece of it works. But we also encounter it as end users: Twitter is the discovery platform today for all things crypto.

One of the things we do differently at Twitter is we build out in the open. And so this means having dialog with customers in real time—designers will take something that is very early-stage and post it as a tweet and then get real-time feedback. They’ll hop into spaces with product managers and engineering managers, talk about it live with real customers, and then incorporate that feedback into the designs and what ultimately we end up launching.

Rinearson: One of the things I wanted to make sure of before I came to Twitter was to know that we would be able to build features in the open and solicit feedback and show rough drafts. And so this is something I asked Parag Agrawal, who’s now the CEO, and was the person who hired me. Pretty early in the job interview process, I said this was going to be really important, and he said, “If you think it’s important to the success of this work, great, do it—thumbs up.” He also shares that openness.

As you said, Tess, you come from crypto. When you were out there, what did you think Twitter was getting right? What did you think Twitter was getting wrong?

Rinearson: I had been a Twitter power user for a really long time. The thing that I saw was a lot of aesthetic alignment between how Twitter exists in the world and the way that crypto exists in the world. Twitter has decentralized user experiences in its DNA. And, this is a bit cheesy, but people use Twitter sometimes in ways that they use a public blockchain, as a public database where everything’s time stamped and people can agree on what happened.

And for most people it’s open, it is there for public conversation. And then obviously it was also the place—a place—where the crypto community really found its footing. I think it’s been a place where an enormous amount of discovery happens, and education and learning for the whole community. I joined when there were some murmurings about Twitter starting to do crypto stuff, mostly stuff Esther had led actually, and I was excited to see where it was going. And then Twitter’s investment in Bluesky also gave me a lot of confidence.

Let’s talk about the two main things you have delivered so far: The crypto tipping feature and NFT pictures. Can you give me just a potted history of how each came about and why?

Crawford: Those are our first set of early explorations, and the reason why we started there was we really wanted to make sure that what we built benefited creators, their audiences, and then all the conversations that are happening on Twitter. For creators in particular, we know that they rely on platforms like Twitter to monetize and earn a living, and not all people are able to use traditional currencies. Not everybody has a traditional banking account setup.

And so we wanted to provide an opportunity for a borderless payment solution, and that’s why we decided to go ahead and use Bitcoin Lightning as our first big integration. One of the reasons we chose Bitcoin Lightning was also because of the low transaction fees. And we have Bitcoin and Ethereum addresses that you can also put in there [on your Twitter “tipping jar”]. We noticed that people were actually adding information about their crypto wallet addresses in their profiles. And so we wanted to make a more seamless experience, so that people could just tip through the platform, so that it felt native.

With NFT profile pictures, the way that came about was, again, looking at user behavior. People were adding NFTs that they owned as avatars, but you didn’t really know whether they owned those NFTs or not. So we decided to go ahead and build out that feature so that one could actually prove ownership.

That’s similar to how other things developed on Twitter, right? The hashtag, or even even the retweet, were initially just things users invented—by adding the # sign, or by pasting other users’ tweets—and then Twitter made that a feature.

Crawford: Yeah, exactly. Many of the best ideas come from watching user behavior on the platform, and then we just productize that.

Rinearson: Sometimes I’ve heard people call that the “help wanted signs,” and like, keeping an eye out for the “help wanted signs” across the platform. The NFT profile picture was a clear example of that.

How do all these things—these two things and possibly other crypto features coming further down the line—really help Twitter’s bottom line?

Crawford: With creator monetization our goal was to help creators get paid, not Twitter. But Twitter takes a really small cut of earnings. For more successful creators, we take a larger percentage. The way we think about this is, it is part of our revenue diversification.

Twitter today is a wholly ad-based business. In the future we imagine Twitter making money from a variety of different product areas. So Twitter Blue is one of those products—you can pay $2.99 a month and you get additional features, such as the NFT profile pictures. We really think that revenue diversification sits across a variety of areas, and creator monetization is one really small component of that.

As you said, these are just early experiments. Where is Twitter Crypto going next? What’s your vision for crypto technology’s role within Twitter?

Rinearson: The real trick here is to find the right parts of Twitter to decentralize, and to not try to decentralize everything at once—or, you know, make every user suddenly responsible for taking care of some private keys or something like that.

We have to find the right ways to open up some access to a decentralized economic layer, or give people ways that they can take their identity with them, without relying on a single centralized service.

We’re really early in these explorations, and even looking at things like Bitcoin tipping or the NFT profile pictures—we view those features as experiments themselves in a lot of ways and learning experiences. We’re learning things about how our users relate to these concepts, what they understand about them, what they find confusing, and what’s most useful to them. We really want to try to use this technology to bring utility to people and you know, not just like, sprinkle a little blockchain on it for the sake of it. So creator monetization is an area that I’m really excited about because I think there’s a really clear path forward. But again, we’re looking beyond that: We’re also looking at using crypto technology in fields like [digital] identity and [digital] ownership space and also figuring out how we can better serve crypto communities on the platform.

Are you going to put Twitter verified users’ blue ticks on a blockchain, then?

[Laughter]

No?

[More laughter]

OK, moving on. How does the kind of work you do dovetail with Bluesky’s plan to create a protocol for a decentralized social media platform? Is there any synergy there?

Rinearson: I have known Jay [Graber], the Bluesky lead, for a long time, and she and I are in pretty close contact. We check in with each other regularly and talk a lot about problems we might have in common that we’ll both need to solve. There’s an overlap looking at things in the identity area, but at the end of the day, it’s a separate project. She’s pretty focused on hiring her team, and they’re very focused on building a prototype of a protocol. That is different from what Esther and I are thinking about, which is like: There are all these blockchain protocols that exist, and we need to figure out how to make them useful and accessible for real people.

And when I say “real people,” I mean that in a sort of tongue-in-cheek contrast to hardcore crypto nerds like me. Jay is thinking much more about building for people who are creating decentralized networks. That is a very different focus area. Beyond that, I would just say it’s too early to say what Bluesky will mean for Twitter as a product. We are in touch, we have aligned values. But at the end of the day—separate teams.

Why is a centralized Silicon Valley company like Twitter the right place to start to bring more decentralization to internet users? Don’t we have just to start from scratch, build a new platform that is already decentralized?

Rinearson: I started in crypto in 2015, and I have a very vivid memory from those years of watching some of my coworkers—crypto engineers—trying to figure out how to secure some of their Bitcoin like before one of the Bitcoin forks [in which the Bitcoin blockchain split, creating new currencies], and they were panicking and freaking out. I thought there was no way that a normal person would be able to handle this in a way that would be safe. And so I was a little bit disillusioned with crypto, especially from a consumer perspective.

And then last year, I started seeing more interest from people whom I’ve known for a long time and weren’t crypto people. They were just starting to perk their heads up and take notice and start creating NFTs or start talking about DAOs. And I thought that that was interesting, that we were coming around a corner, and it might be time to start thinking about what this could mean for people beyond that hardcore crypto group.

And that was when Twitter reached out. You know, I don’t think that just any centralized platform would be able to bring crypto to the masses, so to speak. But I think Twitter has the right stuff. I think you have to meet people where they are with new technologies: find ways to onboard them and bring them along and show them what this might mean for them. make things accessible. And it’s really, really hard to do that with just a protocol. You need to have some kind of community, you need to have some kind of user base, you need to have some kind of platform. And Twitter’s just right there.

I don’t think I would say that a centralized platform is definitely the way to “bring crypto to the masses.” I do think that Twitter is the way to do it.

But why do the masses need crypto right now?

Rinearson: I don’t know that anyone  needs crypto, and our goal is not to get everyone into crypto. Let’s be clear about that. But I do think that crypto is a potentially very powerful tool for people. And so I think what we are trying to do is show people how powerful it is and unlock those possibilities. It’s also possible that we create some products and features, where people actually don’t even really know what’s happening under the hood.

Like maybe we’re using crypto as a payment rail or again as an identity layer—users don’t necessarily need to know all of those implementation details. And that’s actually something we come back to a lot: What level of abstraction are we talking about with users? What story are we telling them about what’s happening under the hood? But yeah, I would just like to reiterate that the goal is not to just shovel everyone into crypto. We want to provide value for people.

Do you think there is a case for Twitter to launch its own cryptocurrency— a Twittercoin?

Rinearson: I think there’s a case for a lot of things—honestly, there’s a case for a lot of things. We’re trying to think really, really broadly about it.

Crawford: We’re actively exploring a lot of things. It’s not it’s not something we would be making an announcement about.

Rinearson: I think it is really important to stress that when you say “Twittercoin” you probably have a slightly different idea of what it is than we do. And are we exploring those ideas? Yes, we want to think about all of them. Do we have road maps for them? No. But are we trying to think about things really creatively and be really, really open-minded? Yes. We have this new economic technology that we think could unlock a lot of things for people. And we want to go down a bunch of rabbit holes and see what we come up with.

Gian M. Volpicelli is a senior writer at WIRED, where he covers cryptocurrency, decentralization, politics, and technology regulation. He received a master’s degree in journalism from City University of London after studying politics and international relations in Rome. He lives in London.

 

Highlighted Text in BLUE, BLACK, GREEN, RED by Aviva Lev-Ari, PhD, RN

SOURCE

https://www.wired.com/story/twitter-crypto-strategy/

Read Full Post »

Tweets at #WMIF2022 by @pharma_BI & @AVIVA1950 and All Retweets of these Tweets – 2022 World Medical Innovation Forum, GENE & CELL THERAPY • MAY 2–4, 2022 • BOSTON

Real Time coverage: Aviva Lev-Ari, PhD, RN

Updated on 5/9/2022

Lessons on the Frontier of Gene & Cell Therapy – The Disruptive Dozen 12 #GCT Breakthroughs that are revolutionizing Healthcare

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2022/05/09/lessons-on-the-frontier-of-gene-cell-therapy-the-disruptive-dozen-12-gct-breakthroughs-that-are-revolutionizing-healthcare/

2022 World Medical Innovation Forum, GENE & CELL THERAPY • MAY 2–4, 2022 • BOSTON • IN-PERSON

https://pharmaceuticalintelligence.com/2022/05/01/2022-world-medical-innovation-forum-gene-cell-therapy-may-2-4-2022-boston-in-person/

Liked Tweets by Conference Organizers

UPDATED on 5/11/2022

Liked

by Mass General Brigham Innovation

Liked

Aviva Lev-Ari
@AVIVA1950

#genetherapy for tuberous sclerosis complex tested on mice found effective in combination with drug in use longer survival to 150 days 10,000 cases in US per year, gene therapy most promising for this gene malfunction #WMIF2022

Quote Tweet
Mass General Brigham Innovation
@MGBInnovation
·
Take a First Look at Dr. Vijaya Ramesh’s research demonstrating preclinical efficacy of an #AAV-based #genetherapy for tuberous sclerosis complex, setting the stage for future IND-enabling studies & clinical translation. #WMIF2022 @MGH_RI @MGHNeurology youtube.com/watch?v=-I_XiS

Top 6 #WMIF2022 #GCT #CARTTherapy #DisruptiveDozen @MGBInnovation @pharma_BI @AVIVA1950 1 Restoring sight by edit genes 2 A gene editing solution supply of donor organs 3 Cell therapies for blindness 4 RNA to treat brain cancer 5 #GCT for brain disorders 6 fighting viruses

liked 2 of your Tweets

7 to 12 #WMIF2022 @MGBInnovation #GCT #DisruptiveDozen @pharma_BI @AVIVA1950 7 Cell therapies restore gut motility 8 CAR-T at autoimmune diseases 9 Regrowing cells in the inner ear hearing loss 10 tech delivering gene therapies 11 target solid tumors 12 X-chromosome neurodegen

Liked

by Tracy Doyle

#KOL on #Cell therapies: #CAR-T cells and #stem-cell-based approaches is moderator for Cell Therapy Landscape: Marcela Maus, MD, PhD Director, Cellular #Immunotherapy Program, #Cancer Center, MGH Associate Professor, Medicine, HMS @MGBInnovation @pharma_BI @AVIVA1950 #WMIF2022

Global views #GCT Christine Fox, Novartis Gene Therapies C. Baum, MD, Berlin Institute of Health Nicholas Galakatos, PhD, Blackstone Luigi Naldini, MD, PhD Telethon Institute, Kendra Rose, PhD, Bayer #WMIF2022 @MGBInnovation @MassGenBrigham @pharma_BI @AVIVA1950

and 2 others liked your Tweet

#Chronic #Neuroinflammation #MS, #AD, #Parkinsons #GCT #genomics Ole Isacson, MD, PhD @McLean Colin Hill CEO, GNS Spyros P., MD, PhD Vigil, Ransohoff, MD, Abata & Third Rock, B. Stevens, PhD, Boston Children’s R. Tanzi, PhD @MGH #WMIF2022 @MGBInnovation @pharma_BI @AVIVA1950

liked 2 of your Tweets

#fundraising #GCT #startups Panelists: Shelley Chu, MD, PhD Partner, Lightspeed Stephen Knight, MD President, F-Prime Capital Adam Koppel, MD, PhD, Bain Capital Life Sciences Daniel Krizek Portfolio Manager, Citadel #WMIF2022 @MGBInnovation @MassGenBrigham @pharma_BI @AVIVA1950

Retweeted your Tweet

#fundraising #GCT #startups Panelists: Shelley Chu, MD, PhD Partner, Lightspeed Stephen Knight, MD President, F-Prime Capital Adam Koppel, MD, PhD, Bain Capital Life Sciences Daniel Krizek Portfolio Manager, Citadel #WMIF2022 @MGBInnovation @MassGenBrigham @pharma_BI @AVIVA1950

Jean-François Formela, MD, Partner @atlasventure on stage with profound #insights on the #interface and seam line between #Medical applications #investment in #health #innovations #WMIF2022 @MGBInnovation @MassGenBrigham @pharma_BI @AVIVA1950 #vision and #inspirations

Retweeted your Tweet

#1 #global #conference #CGT #WMIF2022 @MGBInnovation World Medical Innovation Forum #translation and #regenerative #medicine #gene #editing #gene #therapy @pharma_BI @AVIVA1950 Therapeutics Promise #CGT for #Cardiovascular #Diseases since 12/26/2015 lnkd.in/dwqM3K3

Liked

by Bob Coughlin

Liked

Aviva Lev-Ari
@AVIVA1950

Quote Tweet
Mass General Brigham Innovation
@MGBInnovation
·
Someone in the US is diagnosed with #Alzheimers roughly every 60 seconds. Dr. Stephen Haggarty @neuro_mgh shares a First Look at his work to prevent the accumulation of toxic proteins that cause age-dependent #neurodegeneration at #WMIF2022. worldmedicalinnovation.org/wp-content/upl
1

Aviva Lev-Ari
@AVIVA1950

Breakthrough in ophthalmic drug delivery new #gel delivery system for eye diseases like #retinitis #pigmentosa #WMIF2022

Quote Tweet
Tracy Doyle
@doylet
·
Michael Young, PhD, Schepens Eye Research Institute @MassEyeAndEar, shares preview of new gel delivery system for eye diseases like retinitis pigmentosa at FirstLook research updates @MGBInnovation #WMIF2022

Image

3

Bob Coughlin
@BobCoughlin

and

liked your Tweet

#1 #global #conference #CGT #WMIF2022 @MGBInnovation World Medical Innovation Forum #translation and #regenerative #medicine #gene #editing #gene #therapy @pharma_BI @AVIVA1950 Therapeutics Promise #CGT for #Cardiovascular #Diseases since 12/26/2015 lnkd.in/dwqM3K3

Liked

by Mass General Brigham Innovation

Liked

Aviva Lev-Ari
@AVIVA1950

Breakthrough in ophthalmic drug delivery new #gel delivery system for eye diseases like #retinitis #pigmentosa #WMIF2022

Quote Tweet
Tracy Doyle
@doylet
·
Michael Young, PhD, Schepens Eye Research Institute @MassEyeAndEar, shares preview of new gel delivery system for eye diseases like retinitis pigmentosa at FirstLook research updates @MGBInnovation #WMIF2022

Image

3

Tweets at #WMIF2022 by

@pharma_BI & @AVIVA1950

Aviva Lev-Ari
@AVIVA1950

Geoff Meacham, PhD BofA Securities w/Panelist: Robert Bradway CEO, Amgen strategies in #drug #design #development addressing #chronic aspects of #cancer and #cardiovascular #WMIF2022

amazon.com
Series A: Cardiovascular Diseases
Visit Amazon’s Series A: Cardiovascular Diseases Page and shop for all Series A: Cardiovascular Diseases books. Check out pictures, author information, and reviews of Series A: Cardiovascular Diseases
2

ReTweets of Tweets at #WMIF2022 by

@pharma_BI & @AVIVA1950

by

@StephenJWIllia2

See at https://twitter.com/StephenJWillia2

Retweets at #WMIF2022 by

@pharma_BI & @AVIVA1950 and by others

Retweeting Tweets or Retweets by

@pharma_BI & @AVIVA1950

Mass General Brigham Innovation
@MGBInnovation

#ICYMI – Yesterday, Dr. Robert Califf

, Commissioner Food and Drugs

, joined us at #WMIF2022 for a Fireside Chat. Watch the full session online NOW on the World Medical Innovation Forum YouTube channel.

youtube.com
2022 WMIF | 1:1 Fireside Chat: Robert Califf, MD, Commissioner Food…
1:1 Fireside Chat: Robert Califf, MD, Commissioner Food and Drugs, FDATazeen Ahmad, Managing Director, Global Research, BofA SecuritiesJ. Keith Joung, MD, Ph…
3

James Beck, PhD
@jbeck_PhD

Looking forward to joining panel on patient perspective on gene & cell therapies @ #WMIF2022. People with #Parkinsons may benefit greatly.

is doing a great job of quickly posting sessions YouTube channel for those who cannot attend.

youtube.com
World Medical Innovation Forum
The World Medical Innovation Forum is a global gathering of more than 1,200 senior health care leaders hosted by Mass General Brigham in the heart of Boston. It was established to respond to the…
4

Aviva Lev-Ari
@AVIVA1950

Geoff Meacham, PhD BofA Securities w/Panelist: Robert Bradway CEO, Amgen strategies in #drug #design #development addressing #chronic aspects of #cancer and #cardiovascular #WMIF2022

amazon.com
Series A: Cardiovascular Diseases
Visit Amazon’s Series A: Cardiovascular Diseases Page and shop for all Series A: Cardiovascular Diseases books. Check out pictures, author information, and reviews of Series A: Cardiovascular Diseases
2

Mass General Brigham Innovation
@MGBInnovation

Dr. Rosana Kapeller

will be shining a light on the #darkgenome in today’s Dr. Is In session “The Mysterious Dark Genome” at #WMIF2022. Join her and experts from

,

,

,

and

at 11:45 AM in the St. George room.

Erica Robinson
@eleighrobs

May is Brain Tumor Awareness Month. This is my brilliant neurosurgeon

who has been named the new Chief Medical Officer of

. Congratulations! I was blessed to get connected with you in 2010. #BTSM #BTAM

Quote Tweet
Mass General MDs
@MassGeneralMDs
·
Congratulations to William Curry, MD, @WTCNeuroscience the new chief medical officer of #MassGeneral and the MGPO, effective 6/1. We know he will continue his work to improve the outcomes for patients and train the next generation of leaders. @MGHNeurosurg

Image

1
11

Aviva Lev-Ari
@AVIVA1950

#WMIF2022 #glioblastoma, the most common malignant brain tumor, and one of the most treatment-resistant and fatal human diseases

Read the full abstract here: worldmedicalinnovation.org/wp-content/upl

Quote Tweet
Mass General Brigham Innovation
@MGBInnovation
·
Dr. Anna Krichevsky shares a First Look at her work developing #RNA-targeting therapies for #glioblastoma, the most common malignant brain tumor, and one of the most treatment-resistant and fatal human diseases. #WMIF2022 Read the full abstract here: worldmedicalinnovation.org/wp-content/upl

Image

3

Aviva Lev-Ari
@AVIVA1950

Quote Tweet
Bob Coughlin
@BobCoughlin
·
Great way to start the week. @MGBInnovation World Medical Innovation Forum. 3 days of #CGT talks! #WMIF2022 @MassGenBrigham #worldclass #PatientDriven TY @ChrisMarkCOBURN and team for all you do for patients! @JLL #lifesciencebroker

Image

Image

Read Full Post »

We Celebrate TEN Years of Excellence, LPBI Group: 4/2012 – 4/2022

Author: Aviva Lev-Ari, PhD, RN, LPBI Group Founder

  • 1.0 LPBI: 4/2012 – 12/2022
  • 2.0 LPBI: 1/2021 – Present to 2025

See as well,

2022 Update from LPBI Group 

This article has five parts:

Part 1: Web Site Statistics

Part 2: 2.0 LPBI Group’s Four Missions: The Pipelines for 2021-2025

Part 3: Portfolio of IP Assets

Part 4: Certificates – One Year Academic Internships in six Disciplines

Part 5: Top 14 Articles by Views, All Time

https://pharmaceuticalintelligence.com/2022/02/21/update-from-lpbi-group/

For ten years, now, Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston, MA – flagship Journal had amassed +2.1 MM views

http://pharmaceuticalintelligence.com

2022 Update from LPBI Group

Author & Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2022/02/21/update-from-lpbi-group/

The Founder has  8,148 followers  on LinkedIn.com

https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/aviva-lev-ari-phd-rn-founder-lpbi-group-1-0-2-0/

Analytics of e-Reputation

https://pharmaceuticalintelligence.com/2022/04/04/analytics-for-e-reputation-based-on-linkedin-1st-degree-connections-7500-of-lpbi-groups-founder-2012-2022-an-intangible-asset-connections-position-seniority-biotech-pharma-focus/

The Founder is the Editor-in-Chief for the Journal and for the BioMed e-Series – an eighteen volume series of electronic Books in Medicine

https://lnkd.in/ekWGNqA

Page downloads on 4-6-2022

N = 147,069 (till end of Feb. 2022)

Equivalent to 74 Books

Abbreviated electronic Table of Contents (eTOCs) of each Volume in the EIGHTEEN-Volume BioMed e-Series

https://pharmaceuticalintelligence.com/2017/12/12/biomed-e-series-16-volumes-electronic-table-of-contents-of-each-volume/

The Team that produced 18 books in Medicine

https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/

LPBI Group’s CSO, 2012-2017: Dr. Larry H. Bernstein, MD, FCAP

https://pharmaceuticalintelligence.com/contributors-biographies/members-of-the-board/larry-bernstein/

The Founder is a UC, Berkeley PhD’83 who had worked at Director Level for SRI Int’l, MITRE, PSC, McGraw Hill. Other employer organizations includes: Monitor Company (now Deloitte), Amdahl Corporation (now Fujitsu), PSC (now Dell Technologies).  Positions in Healthcare are described in this link: http://Scientific and Medical Affairs Chronological CV

Aviva Lev-Ari, PhD, RN

Director & Founder

https://lnkd.in/eEyn69r

Picture date: 2/6/2022

While you are reviewing LPBI Group’s Portfolio of IP assets

https://pharmaceuticalintelligence.com/portfolio-of-ip-assets/

you will note that LPBI Group is venturing into Scientific NFT Marketplaces

https://pharmaceuticalintelligence.com/nft-redefined-format-of-ip-assets/

We plan to MINT as NFTs several of LPBI Group’s IP Asset Classes, such as

  • Curations among our +6,100 Journal articles – IP Asset Class I
  • eTOCs – Electronic Table of Contents of our 18 Books – IP Asset Class II
  • Gallery of +6200 Biological Images embedded in our Journal articles – IP Asset Class V
  • E-Proceedings of +100 Medical and Biotech Conferences we had covered in Real Time, 2013 – 2022 – IP Asset Class III
  • Tweet Collections of the latest 40 Medical and Biotech Conferences we had covered in Real Time, 2013 – 2022 – IP Asset Class III

Examples:

Tweet Collection of 2022 #EmTechDigital @MIT, March 29-30, 2022

https://pharmaceuticalintelligence.com/2022/04/02/tweet-collection-of-2022-emtechdigital-mit-march-29-30-2022/

Analytics for @AVIVA1950 Tweeting at #EmTechDigital

https://pharmaceuticalintelligence.com/2022/04/11/analytics-for-aviva1950-tweeting-at-emtechdigital/

Review our Testimonials

https://pharmaceuticalintelligence.com/praising-lpbi/

Our PAST is here

https://pharmaceuticalintelligence.com/home-website-front-page/

https://pharmaceuticalintelligence.com/2019-vista/

 

Our FUTURE is here

https://pharmaceuticalintelligence.com/vision/

https://pharmaceuticalintelligence.com/blockchain-transactions-network/

https://pharmaceuticalintelligence.com/synthetic-biology-in-drug-discovery/

https://pharmaceuticalintelligence.com/2021-medical-text-analysis-nlp/

https://pharmaceuticalintelligence.com/2021/07/24/proposal-for-new-e-book-architecture-combining-a-bi-lingual-etocs-english-spanish-with-nlps-results-of-medical-text-analysis-series-b-genomics-volume-1-2-and-series-c-cancer-volume-1/

Podcast of our Leaders are here

https://pharmaceuticalintelligence.com/audio-podcasts/

A stream of Ten INNOVATIONS in the Life of LPBI since

inception in 2012 to 2022

  1. 4/2012 – LPBI was the Launcher of a novel Scientific Curation Methodology for scientific findings in published primary research in the Global e-Scientific Publishing industry https://pharmaceuticalintelligence.com/
  2. As late as 2016, no big publisher, not even one, i.e., Elsevier, John Wiley had curation-based publications: Journals, Books, e-Proceedings or Gallery of thousands of Biological Images as an IP asset class
  3. At LPBI, Curation of scientific findings was performed in +6,000 articles with +2MM e-Views by Global e-Readers
  4. 6/2013 – LPBI was the Publisher of the 1st e-book in Medicine in Kindle Store on the Life Sciences & Medicine Shelf – Upload to this shelf by Amazon.com
  5. 2/2021 – Completion of the 18 volumes, BioMed e-Series in five Specialties in Medicine: each article in each volume is a curation-based publication.
  6. On Amazon.com on 7/2021 – LPBI’s e-books in Medicine enjoy +128,100 PAGE DOWNLOADS – the ONE and ONLY publisher in that range of page downloads. The record is the equivalent of 64 books at an average of 2,000 pages a volume !!!! LPBI smallest book is 1,000 pages and its biggest is +3,700 pages
  7. LPBI launched its Natural Language Processing (NLP) Practice in 1/2020 as Mission #1. NLP is one method of Machine Learning (ML). ML is a family of methods in Artificial Intelligence (AI) which is a field in the Computer Science Academic discipline since the early 60s.
  8. In 4/2021 Linguamatics/IQVIA performed NLP on LPBI’s 33 articles and 20 Biological Images. RESULTS:  +670 entity relations DISCOVERED by Linguamatics and unknown to Pharma and to Insurers, entity relations between:
  • Gene-Disease
  • Gene-Drug
  • Disease-Drug

These results were jointly presented to a Healthcare Insurer, SLC, UT on 7/13/2021, forthcoming meeting in 9/2021.

LPBI and BurstIQ are architecting NOW the first Natural Language Processing – Blockchain Information Technology infrastructure in existence, This statement is TRUE.

  • Updated on 7/28/2021:Fluree Flur.ee, the Web3 Data Platform Open source semantic graph database & LeadSemantics.com presented their solution for NLP and Blockchain on 7/28/2021. Erich G. was lured as Chief architect for LPBI’s Mission #2: NLP & Blockchain
  • Linguamatics, the leader in NLP did not hear of Blockchain and BurstIQ did not have a request for NLP – LPBI PUT THESE TWO TECHNOLOGIES AND PARTIES TOGETHER

See IMAGES SOURCE: BurstIQ image for LPBI

https://pharmaceuticalintelligence.com/2021/03/02/2-0-lpbi-is-a-very-unique-organization/

  • On 7/19/2021 – LPBI had launched LPBI India for Synthetic Biology Software for Drug Discovery targeting Galectins – Collaboration with Dr. Raphael Nir, President and CSO, SBH Sciences, Inc., Natick, MA
  • On 7/25/2021 – LPBI announced that it will have the NEWLY to be published BioMed e-Books As Mission #3:
  • A NEW Publishing GENRE of SCIENTIFIC BOOKS

o    Bi-Lingual electronic Table Of Contents (eTOCs), English & Spanish with Montero Language Services, Madrid as the Translator of eighteen Books’ Cover Pages and the 18 books electronic Table of Contents.

o    The Content promotion in the Spanish speaking Countries with GTO, Madrid as AD Agency.

o    NLPs results of Medical Text Analysis with domain knowledge expert Interpretations in Foreign Languages and in Audio: in Spanish and in other languages, forthcoming

o    Original English Book – Only Editorials (Preface, Introductions, Summaries and Epilogue) because the Bi-Lingual part has the eTOCs of the e-Book

o    This is a new genre and a new architecture of 18 MULTIMEDIA SCIENTIFIC e-Books with (a) NLP results of the Medical Text analysis with machine learning, (b) Expert Interpretation of the Visualization Results. Bi-Lingual Podcasts: (c) eTOCs and (d) Bi-Lingual Expert Interpretation in English and Spanish Text and audio Podcasts, and (e) Books’ Editorials in English Audio Podcast

Content promotion proposal by GTO, Madrid

See IMAGES SOURCE: Rendition by GTO, Madrid of BurstIQ Image, above

2.0 LPBI is a Very Unique Organization 

9. The Content Monetization effort includes the Price List for LPBI 1.0 digital products and of LPBI 2.0 – NLP Products

Under development

  • IP Valuation Model per IP asset class is needed to be compared with Master_Financials and to supplement it
  • Pricing Model and Product Mix Models for the digital products to be generated by the process of Text Analysis with NLP are using a Product Price List already developed.
  • The scenarios for a Probabilistic Product Mix for the B2B sector are work-in-progress. Scenarios of Product Mix for $500,000 B2B engagements with NLP scaling up with NLP Alliances. The Alliances are the Labor component and LPBI represent Materials (Content) as 25% of the contract price, on top of total, to be paid by the B2B customer as materials in use for the engagement.
  • B2C Customers on Blockchain will use the Price List for all Digital Products of LPBI 1.0 and LPBI 2.0 – Pay per Use

10. LPBI Group runs FIVE ACADEMIC INTERNSHIPS as Certificate Programs: a One Year long or a One Semester long: Volunteer base offering Verifiable Certificates, as described in https://pharmaceuticalintelligence.com/certificate-1-year/

Read Full Post »

Analytics for @AVIVA1950 Tweeting at #EmTechDigital

Reporter and Curator: Aviva Lev-Ari, PhD, RN

Data SOURCE

https://analytics.twitter.com/user/aviva1950/tweets

See also

Tweet Collection of 2022 EmTechDigital @MIT, March 29-30, 2022

Tweet Author: Aviva Lev-Ari, PhD, RN

Selective Tweet Retweets for The Technology Review: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2022/04/02/tweet-collection-of-2022-emtechdigital-mit-march-29-30-2022/

TWEET HIGHLIGHTS

Top Tweet earned 122 impressions

Prem Natarajan Vice President Alexa AI device and broadly decisions what stay on edge vs cloud physical obstacles to learn language less constrained Alexa5 more creative
 1  2

Top mention earned 7 engagements

Agrim Gupta, Stanford Vision Learning Lab, Stanford University Baldwin Effect genotypic modification phynotypic behavior GPT-OpenAI CLIP MetaMorph process transformer Encode Decode
 1  1
Impressions
Engagements
Engagement rate
18
1
5.6%

Read Full Post »

Equity Sharing Calculation: A Scoring System for Author’s (a) Total Articles (single author) and (b) multiple authors)(c) Total Articles Views and (d) Author’s Proportion of own articles views in the Top 14 Journal articles by Views (e) External Citations

Curators: Aviva Lev-Ari, PhD, RN and Stephen J. Williams, PhD

LPBI Group had developed a Scoring System for attribution of Equity Sharing in IP Asset Class I: Journal articles to Top Authors by number of articles published and by Views at all time for all articles published in the Journal

UPDATED on 5/24/2022

(e) External Citations

More details are found in

https://pharmaceuticalintelligence.com/2020/12/08/papers-citing-pharmaceuticalintelligence-com/

 

(a) Author’s Total Articles (single author) 

(b) Author’s multiple authors articles